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TIMP-1, an B30kDa glycosylated protein found predominantly in extracellular compartments, is involved in the regulation of a
variety of developmental, remodelling, and pathological processes. One function of TIMP-1 is to inhibit certain members of a group of
extracellular and cell surface enzymes known collectively as metalloproteinases (MP). These include the matrix metalloproteinases
and the adamalysin-like disintegrin and metalloproteinases (ADAMs). Additional activities of TIMP-1 include potentiating the activity
of erythroid precursors and stimulating proliferation of certain cancer cell lines. Published evidence suggests that the apparent
proliferative action of TIMP-1 is independent of its MP-inhibitory activity; however, reports of a cell surface receptor for TIMP-1 have
not been confirmed. We have utilised a baculovirus-based system to produce TIMP-1. Data presented here show that TIMP-1 and
synthetic hydroxamate (GM6001) MP inhibitors stimulate proliferation and metabolic activity of MDA-MB-435 cancer cells with
similar kinetics. An inactive hydroxamate derivative was ineffective. The TIMP-1-induced increase in proliferation and metabolic
activity was not the consequence of the inhibition of apoptosis by TIMP-1 in the serum-free medium. These data taken together
imply that the mechanism by which TIMP-1 enhances cell growth depends on its ability to inhibit a metalloproteinase, rather than to
stimulate a cell surface receptor by a process independent of its MP-inhibitory activity. Inhibitors of extracellular regulated kinase
(U0126) and p38 (SB203580), and to a lesser extent the phosphatidylinositol-3-kinase inhibitor LY294002, suppressed the action of
TIMP-1. Assays for ERK1/2 and p38 showed that both were activated by TIMP-1 and GM6001. Mechanisms by which TIMP-1 might
act to stimulate cell proliferation are described.
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Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an N-
glycosylated, secreted protein that is found in plasma and other
body fluids (Brew et al, 2000). Six disulphide bonds maintain the
protein’s structure and define two domains, an N-terminal
inhibitory domain and a C-terminal regulatory domain. The
disulphide bonds are a hindrance to the production of properly
folded, active recombinant TIMP-1 in bacterial systems, although
some successes have been reported (Cocuzzi et al, 1992; Kleine
et al, 1993; Huang et al, 1996; Rajan et al, 1998; Davis et al, 2001).
Here, we have utilised a baculovirus-based system to produce post-
translationally modified and secreted TIMP-1 in insect cells.
The primary function of the TIMPs (four are known) is to
inhibit various members of a group of ectoenzymes known as MPs,
which include the adamalysin-like disintegrin and metalloprotei-
nase (ADAM) and matrix metalloproteinase (MMP) families (Brew
et al, 2000). MPs function in various physiological and pathophy-
siological processes, such as ovulation, embryogenesis, angiogen-
esis, wound healing and metastasis, that involve remodelling of the
extracellular matrix (Chambers and Matrisian, 1997; Nagase and
Woessner, 1999; Brew et al, 2000). TIMP-1 regulates these
processes by virtue of its ability to inhibit MPs.
Paradoxically however, TIMP-1 expression has been found to be
elevated in certain malignancies, and high levels of TIMP-1
expression in tumours, by either tumour or stromal cells, are
predictive of poor patient prognosis with regard both to the length
of the disease-free interval and to survival rate (Ree et al, 1997;
McCarthy et al, 1999; Nakopoulou et al, 2002). Therefore, if TIMP-
1 can inhibit MPs and tumorigenicity, as has been shown for
example in studies with murine melanoma cells (Walther and
Denhardt, 1996), then why is increased expression in patients with
cancer linked to a poor prognosis (Denhardt, 2000)?
An answer to this question was suggested by the studies of
Hayakawa et al (1992) showing that TIMP-1 could promote the
growth of a variety of normal and transformed cells, a property
reminiscent of its erythroid potentiating activity (Golde et al, 1980;
Docherty et al, 1985; Avalos et al, 1988). Additionally, two breast
cancer cell lines, MCF-7 and BC-61, have been shown to respond to
TIMP-1 by an increase in proliferation. MCF-7 cells that were
grown in medium containing foetal calf serum immunodepleted of
TIMP-1 grew less well than cells in the same medium supple-
mented with TIMP-1 (Hayakawa et al, 1992).
Growth of BC-61 cells was stimulated by TIMP-1 in a dose-
dependent fashion, and there was an increase in protein tyrosine
phosphorylation; these cells expressed an 80-kDa transmembrane
protein that could bind TIMP-1 both in vivo and in vitro
(Luparello et al, 1999). In those cancers associated with high
levels of TIMP-1 expression, it appears that TIMP-1 drives tumour
progression as the result of its ability to stimulate proliferation.
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promoting function have been reported to be independent of one
another (Hayakawa et al, 1994; Chesler et al, 1995), suggesting that
TIMP-1 may have a second mode of action having nothing to do
with its ability to inhibit MPs (Baker et al, 2002). That is the issue
addressed in this paper. Evidence presented here strongly suggests
that the proliferation caused by TIMP-1 treatment of MDA-MB-
435 cells is the result of TIMP-1 inhibiting one or more MPs.
Additionally, our results show that the growth stimulus results
from the activation of MEK, p38, and to a lesser extent PI3K, in
cells treated with either TIMP-1 or a synthetic MMP inhibitor.
MATERIALS AND METHODS
TIMP-1 production and purification
The entire cDNA, including the signal sequence, encoding human
TIMP-1 (a generous gift of Dr Dylan Edwards, University of East
Anglia, UK) was subcloned into the pIZ/V5-His plasmid in frame
with the C-terminal histidine tag. BTI-TN-5B1-4 insect cells
(Trichoplusia ni, the cabbage looper, grown in Express Five
Serum-Free Medium) were then transfected with the pIZ/hTIMP-
1V5-His plasmid using CellFECTIN (all products obtained from
Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Transfected cells were selected by addition of Zeocin
(from Invitrogen, Carlsbad, CA, USA) to the medium at a
concentration of 600mgml
 1. Pools of clones were isolated and
conditioned medium was examined by Western blot analysis for
the presence of human TIMP-1. The medium conditioned by these
cells can be collected from cultures maintained for up to 2 months.
The protein was purified from the conditioned medium with use of
a nickel chelating resin according to the manufacturer’s instruc-
tions (Novagen, Madison, WI, USA). The eluted fractions were
analysed on Western blots for the presence of human TIMP-1. The
fractions containing TIMP-1 were pooled and dialysed against
20mM PIPES (Piperazine-N,N0-bis-[2-ethanesulphonic acid]) (pH
6.0) and 50mM NaCl. The dialysed sample was applied to a
sulphonylpropyl cation exchange resin and eluted using 1.0 M NaCl
buffer. The eluted fractions were tested by OD280 for the presence
of protein and the fractions at the peak were pooled and
concentrated using a Centriprep concentrator from Amicon
(Beverly, MA, USA). The concentrated sample was then electro-
phoresed on a 15% SDS–PAGE gel using a nonreducing loading
buffer (Leber and Balkwill, 1997). A small portion of the gel was
stained with Coomassie Brilliant Blue R-250 (Sigma, St Louis, MO,
USA). The band corresponding to the molecular weight of human
TIMP-1 was excised and the gel slice was cut into cubes of about
1mm
3 and electroeluted in a 10000 MWCO dialysis bag and 10ml
of TAE buffer (40mM Tris-acetate and 2mM EDTA, pH¼8.5)
overnight at 45V and 41C. After a brief centrifugation to remove
gel fragments, the supernatant was lyophilised and resuspended in
1ml of 250mM NaCl and 20% glycerol. The protein suspension was
then filtered using a 0.22-mm filter and the protein was quantified
using OD280 and an extinction coefficient of 1mgml
 1 (Gill and
Hippel, 1989).
The results of a typical purification procedure starting with
400ml of medium conditioned by insect cells permanently
transfected with a TIMP-1-expressing vector are shown in
Table 1. The three-step purification procedure yielded approxi-
mately 1mg of pure TIMP-1 (MW B30kDa) per litre of
conditioned medium. The purity (495%) of the TIMP-1 prepara-
tion was assessed by Western blotting and silver staining of an
SDS–PAGE gel (inset in Figure 1). A collagenase inhibition assay,
detailed in the next paragraph, was used to confirm the MMP-
inhibiting activity of the purified TIMP-1. Figure 1 shows the result
of a typical inhibition assay. Maximum inhibition occurred at
750ng of TIMP-1, which corresponds to an approximate 1:1 molar
ratio of TIMP-1 to active MMP-1 (MW B43kDa), suggesting that
the majority of both proteins in the preparations were functional.
TIMP-1 activity assay
The MP inhibitory activity of the purified recombinant TIMP-1
was measured using human fibroblast collagenase (MMP-1, a
generous gift of Dr Howard Welgus, Washington University School
of Medicine, St Louis, MO, USA) and fluorescein-labelled collagen
type I (Molecular Bioprobes, Eugene, OR, USA). An optimisation
was done to determine the optimal amount of MMP-1 and
fluorescein-labelled collagen for the activity assay. (Data not
shown.) Briefly, differing amounts of purified TIMP-1 were mixed
with 1mg MMP-1 in collagenase buffer (50mM Tris-Cl pH 7.4, 0.2 M
NaCl, 5mM CaCl2 and 0.05% Brij-35) in a total volume of 95ml. The
mixture was allowed to incubate for 1h at room temperature to
allow TIMP-1 and MMP-1 to associate. Following this incubation,
Table 1 Protein purification table for recombinant human TIMP-1 from a baculoviral-based system
Step Total protein (mg) Percent recovered protein Total activity (U) Percent recovered activity Specific activity (Umg
 1)
Medium 355.6 100 4597 100 12.93
Nickel column 8.4 2.4 1822 39.6 216.9
Sulphopropyl column 2.9 0.82 1007 21.9 347.2
Electroeluted 0.424 0.12 712.7 15.5 5525
Data are from a typical recombinant human TIMP-1 protein purification starting with 400ml of medium conditioned by permanently transfected insect cells. Protein and activity
levels were determined as described in Materials and Methods.
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Figure 1 Inhibition of MMP-1 by purified TIMP-1 with inset figure of
silver-stained SDS–PAGE and Western blot of purification steps for TIMP-
1. Concentration-dependent inhibition of human fibroblast collagenase
activity by purified human TIMP-1. The TIMP-1 concentration of 750ng
corresponds to a 1:1 molar ratio of enzyme to inhibitor. The inset consists
of two parts; the top part is a silver stain of the fractions from each step in
the purification of hTIMP-1. Lane 1 contains medium conditioned by
transfected insect cells; lane 2 contains pooled fractions from a nickel
column; lane 3 contains pooled fractions from an SP-cation exchange
column; and lane 4 shows the electroeluted human TIMP-1. The bottom
part is a Western blot of the same fractions showing a single band
corresponding to hTIMP-1.
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robes), in 5ml, was added to each reaction. Fluorescence was
measured using a Packard FluoroCount immediately after the
addition of the collagen. The reactions were incubated in the dark
at room temperature overnight. The next day a second fluorescent
reading was taken and the first reading was subtracted from the
second reading. The result was compared to a positive and
negative control for collagen digestion to determine the amount of
inhibition of MMP-1 by TIMP-1.
Cell growth assays
Alamar Blue dye was purchased from Biosource International Inc.
(Camarillo, CA, USA) and the manufacturer’s instructions were
followed to complete the assay (Ahmed et al, 1994; Nakayama et al,
1997). Briefly, MDA-MB-435 cells were plated in a 24-well dish in
aMEM supplemented with 10% foetal bovine serum, 2mM
glutamine, 50Uml
 1 penicillin, and 50mgml
 1 streptomycin at a
cell concentration of 15000cellswell
 1. (All cell culture media
were obtained from Invitrogen.) Cells were allowed to attach
overnight and the medium was replaced with aMEM supplemented
with 1% bovine serum albumin (Sigma cell culture grade BSA,
Catalog # A1933), 2mM glutamine, 50Uml
 1 penicillin, 50mgml
 1
streptomycin and 10% Alamar Blue dye; the desired amount of
TIMP-1 or synthetic inhibitor was also added. In experiments
using a signal transduction inhibitor, the appropriate amount of
signal transduction inhibitor was added and an initial incubation
at 371C and 5% CO2 for 1h was done before the addition of TIMP-
1. A Packard FluoroCount instrument was used to determine the
amount of Alamar Blue reduced by measuring the fluorescence of
the reaction mixture (excitation 530nm, emission 590nm).
Tritiated thymidine incorporation was quantified as described
(Rittling et al, 2002). Briefly, cells were plated in complete medium
in a 24-well dish at a concentration of 15000cellswell
 1 and
allowed to attach overnight. The next day the wells were rinsed 3 
with phosphate-buffered saline (PBS); serum-free medium with 1%
BSA was then added along with the appropriate amounts of TIMP-
1 or synthetic inhibitor. The cells were then labelled, after
incubation for differing time periods, with [
3H]thymidine
(1mCiml
 1 of medium) for 5h. The medium was then removed,
the cells were rinsed once in ice-cold PBS and the cells in each well
lysed with 500ml of 7% trichloroacetic acid on ice for 30min. The
plate was centrifuged at approximately 500g, the supernatant
removed, and the precipitate solubilised in 200ml of 0.5 M NaOH
and 0.5% SDS. Radioactivity, typically ranging from 10
4 to 10
5
c.p.m.sample
 1 in the solubilised precipitate, was determined with
a Beckman scintillation spectrometer.
Apoptosis assay
The apoptosis assay was performed using the Cell Death Detection
ELISA Plus kit purchased from Roche-Applied Science (Penzberg,
Germany, Catalog # 1 774 425). The manufacturer’s protocol was
followed to determine the level of apoptosis in MDA-MB-435 cells
untreated or treated with TIMP-1 or synthetic inhibitor. Briefly,
MDA-MB-435 cells were seeded into a 24-well dish at a
concentration of 1.5 10
4cellswell
 1 and allowed to attach
overnight. The next day the wells were rinsed 3  with PBS and
1ml of aMEM with 1%BSA was added to each well, followed
immediately by the addition of TIMP-1, synthetic inhibitor, or the
PBS vehicle. The cells were incubated for 24h at 371C with 5% CO2.
Then the plate was centrifuged and the supernatant was carefully
removed. The cell pellet was placed into 200ml of lysis buffer
provided by the manufacturer for 30min, after which time it was
centrifuged. Aliquots of the supernatant (20ml) were used in an
ELISA with anti-DNA and antihistone antibodies to detect the
presence cytoplasmic nucleosomes. Advantages of this assay
include the lack of subjectivity in interpreting the results, and
further that it is sensitive enough to detect as few as 300 apoptotic
cells.
Synthetic MP inhibitors
GM6001 (Galardin, Ilomastat) and its inactive analog (N-t-
butoxycarbonyl-L-leucyl-L-tryptophan methylamide) were ob-
tained from Calbiochem (San Diego, CA, USA). BB94 (Batimastat)
was a generous gift of Dr Dylan Edwards, University of East Anglia,
UK.
Signal transduction inhibitors
Signal transduction inhibitors (U0126, SB203580, LY294002,
genistein, and H-9) were obtained from Tocris Cookson Inc.
(Ellisville, MO, USA).
ERK1/2 (p44/42) and p38 kinase assays
Kinase assay kits for both ERK1/2 (p44/42) and p38 were
purchased from Cell Signaling Technologies, Beverly, MA, USA.
The manufacturer’s protocol for the assays was followed. Briefly,
4 10
5 MDA-MB-435 cells were plated in 10-cm dishes and
allowed to attach overnight. The next day the cells were rinsed 3 
with PBS and 5ml of serum-free aMEM with 1% BSA was added
and the cells were serum-starved overnight. The next day the cells
were again rinsed 3  with PBS and 5ml of fresh aMEMþBSA
medium with either TIMP-1, the synthetic hydroxamate inhibitor,
or PBS vehicle. The cells were then incubated at 371Ci n5 %C O 2
for 20–30min. The cells were then harvested in lysis buffer
(provided by the manufacturer) with a cell scraper. Protein from
the cell lysate amounting to 200mg for each p44/42 assay and
400mg for each p38 assay was added to an immunoprecipitation
reaction overnight at 41C to precipitate active p44/42 and p38,
respectively. Kinase activity in the immunoprecipitates was
assessed with either Elk-1 or ATF-2 as substrate for p44/42 and
p38, respectively. The reaction mixtures were then electrophoresed
on a 12% SDS–PAGE gel, blotted and probed for phosphorylated
Elk-1 or ATF-2 using antibodies specific for the phosphorylated
protein. The intensities of the bands generated on films of the gels
were then quantified (in the linear range) using Kodak 1D Image
Analysis Software (Eastman Kodak Company, Rochester, NY,
USA).
Statistical analysis
Statistical analysis was done using the Student’s t-test.
RESULTS
TIMP-1 stimulates cell proliferation
As noted in the introduction, TIMP-1 stimulates the growth of
several transformed cell lines. We have used two different
strategies to extend these studies. In one study, we assessed
metabolic activity while in the second, we measured the rate of
DNA synthesis, in both cases as a function of TIMP-1 concentra-
tion and exposure time. Figure 2A and B show that TIMP-1
stimulated MDA-MB-435 by both criteria. Although generally
considered a breast carcinoma line, recent evidence based on gene
expression profiling has suggested that MDA-MB-435 may have
been derived from an occult melanoma metastatic to the breast
(Ellison et al, 2002). In Figure 2A, the respiratory rate of the cells
treated with TIMP-1 increased by approximately 2.5-fold within
the first 6h of incubation in comparison with the untreated cells.
Alamar Blue is reduced in proportion to mitochondrial respira-
tion, and is thus an indicator of the overall rate of anabolic activity
in the cell culture. In Figure 2B, the amount of DNA synthesis as
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3H]thymidine incorporation increased by almost
two-fold 24h after incubation with 4nM TIMP-1 in comparison
with the untreated cells, suggestive of a substantial increase in the
rate of DNA replication. The concentration at which TIMP-1
caused maximal stimulation was 4nM, in agreement with previous
studies (Hayakawa et al, 1992, 1994; Yamashita et al, 1996). (Above
4n M there was no further stimulation of proliferation or metabolic
activity, data not shown.) These actions of TIMP-1 are unlikely to
be the consequences of endotoxin contamination both because of
the nonbacterial source of the protein and because an endotoxin
assay (Sigma E-Toxate kit) revealed no evidence of endotoxin.
Previous literature reports suggest that the proliferation caused
by TIMP-1 occurs through its interaction with a putative cell
surface receptor and not through its interaction with an MP
(Hayakawa et al, 1994; Chesler et al, 1995). In order to better
address this question, we asked whether the synthetic MP inhibitor
GM6001 (also known as Ilomastat or Galardin) and also an inactive
derivative of GM6001 as a control, could similarly stimulate
metabolic activity and DNA synthesis. GM6001 has been reported
to inhibit MMP-1, -2, -3, -8, and -9 (Galardy et al, 1994a,b). As can
be seen in Figure 2C, 4nM GM6001 caused an 80% increase in the
respiratory rate of MDA-MB-435 cells when treated for 6h.
Figure 2D shows a 50% increase in [
3H]thymidine incorporation
in cells incubated with GM6001 for 12h. Very similar results (not
shown) were obtained with BB94, which can inhibit MMP-1, -2, -3,
-7, -9, and -13 (Brown, 1994). At concentrations above 4nM, both
of these inhibitors were unable to increase further either the
respiratory rate or [
3H]thymidine incorporation (data not shown).
In comparison with TIMP-1, GM6001 was somewhat less effective
at stimulating Alamar Blue reduction, but more effective at
stimulating DNA synthesis, particularly in the first 12h. Simulta-
neous exposure of the cells to TIMP-1 and GM6001 did not reveal
evidence for an additive effect (data not shown).
To determine if the stimulation seen by the synthetic MP
inhibitors was dependent upon their ability to inhibit MPs, we
tested an inactive derivative of GM6001 (GM6001*) (Jung et al,
2002). Figure 2E and F shows that the inactive derivative
(GM6001*) had no effect either on the respiratory rate or
[
3H]thymidine incorporation, confirming that the growth-promot-
ing activity of GM6001 was dependent upon its ability to inhibit
MPs. A sensitive apoptosis assay, shown in Figure 3, suggested that
the increase in metabolic activity and DNA synthesis in the
cultures exposed to TIMP-1 was not simply the result of a reduced
amount of apoptosis.
Stimulation of growth by TIMP-1 occurs through the MEK/
ERK and p38 kinase pathways
In BC-61 cells exposed to TIMP-1 tyrosine-phosphorylated
proteins were shown to increase in abundance (Luparello et al,
1999). Additionally, Wang et al (2002) have reported an increase in
Ras-GTP complex formation in MG63 human osteosarcoma cells
treated with TIMP-1. To determine in our studies what signal
transduction pathway(s) is/are critical to TIMP-1-induced signal-
ling, we employed several specific signal transduction inhibitors.
U0126 (a MEK inhibitor), SB203580 (a p38 kinase inhibitor) and
LY294002 (a PI3-kinase inhibitor) were the specific signal
transduction inhibitors used to shed light on the cell signalling
pathways involved (Vlahos et al, 1994; Cuenda et al, 1995; Favata
et al, 1998; Davies et al, 2000). Both MEK and p38 kinase have been
shown to increase cellular proliferation upon activation (Neve et al,
2002; Royuela et al, 2002). PI3-kinase has been shown to inhibit
apoptosis and also cause proliferation upon activation (Neve et al,
2002).
Additionally, two general signal transduction inhibitors were
used: Genistein (an inhibitor of protein tyrosine kinases) and H-9
(an inhibitor of protein kinases including protein kinases A, C and
G, calmodulin kinase II, and casein kinases I and II) (Akiyama et al,
1987; Flickinger, 1988). Activation of PKC has been shown to
contribute to cancer cell proliferation (Jarzabek et al, 2002). Data
generated from the signal transduction inhibitor experiments are
summarised in Figure 4. The two bars at the left show that the
addition of TIMP-1 doubled the amount of Alarmar Blue reduction
in the first 6h under these conditions. The rightmost six bars
represent cells treated with the indicated signal transduction
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Figure 2 TIMP-1 and GM6001 stimulate anabolic activities in MB-MDA-
435 cells in a time- and concentration-dependent manner. Panels (A) and
(B) show, respectively, the enhancement of reduction of Alamar Blue and
the stimulation of incorporation of [
3H]thymidine by the concentration of
TIMP-1 indicated in the inset. Panels (C) and (D) show, respectively, the
enhancement of reduction of Alamar Blue and the stimulation of
incorporation of [
3H]thymidine by the concentration of GM6001 indicated
on the inset. Panels (E) and (F) show, respectively, the lack of
enhancement of reduction of Alamar Blue and no stimulation of
incorporation of [
3H]thymidine by the concentration of inactive GM6001
derivative (GM6001*). In the panels representing the Alamar Blue assays,
the amount of Alamar Blue reduced in each sample was normalised to the
untreated control (100% represents 2 10
3–2 10
4 RFU). Each bar
represents the average of four samples. In the panels representing the
[
3H]thymidine incorporation cells were treated with or without TIMP-1 or
synthetic inhibitors and pulsed for 5h with [
3H]thymidine. (Time on the
abscissa is the time the 5-h pulse with [
3H]thymidine was terminated.) The
amount of [
3H]thymidine incorporated in each sample was normalised to
the untreated control (100% represents 2 10
4–4 10
4 c.p.m.). Each bar
represents the average of four samples. Statistical significance was
calculated using the Student’s t-test; *represents a P-value of 0.05 or less
and # represents a P-value o0.01; RFU: relative fluorescence unit.
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completely inhibited the increase in metabolic rate seen at 6h
when TIMP-1 alone was added to the cells. LY294002 and H9
appeared to inhibit partially the metabolic rate increase seen when
the cells were treated with TIMP-1 alone.
To confirm that the MEK/ERK and p38 kinase pathways are
involved in TIMP-1 cell proliferation, ERK and p38 kinase activity
assays were done on treated and untreated cells. The ERK assays
are pictured in Figure 5A; the band shown represents phosphory-
lated recombinant Elk-1, phosphorylated by immunoprecipitated
ERK from MDA-MB-435 cancer cells. TIMP-1-treated cells
exhibited a transient two-fold increase in ERK activity at 20min
as measured by the intensity of the phosphorylated Elk-1
(Figure 5B). By 30min the ERK activity was back to baseline.
Similarly, the cells treated with the synthetic MMP inhibitor
GM6001, but not its inactive derivative, showed the same transient
increase in ERK activity. The p38 kinase assays are shown in
Figure 5C; the band shown represents phosphorylated recombi-
nant ATF-2, phosphorylated by immunoprecipitated p38 kinase
from MDA-MB-435 cells. TIMP-1, GM6001, and the inactive
derivative of GM6001 all show the same effect on p38 kinase
activity in the MDA-MB-435 cells. Activity of p38 kinase is
ultimately increased in the treated cells by a factor of 2 by 30min
post-treatment as indicated by the densitometry data shown in
Figure 5D. Similar results were obtained in a repeat experiment for
both kinases.
DISCUSSION
TIMP-1 stimulates cell growth by inhibiting an MP
TIMP-1 has been shown to enhance proliferation of erythroid
progenitors as well as certain transformed mammalian cell lines
(Golde et al, 1980; Docherty et al, 1985; Hayakawa et al, 1992).
Since TIMP-1 was first described as erythroid potentiating activity
[EPA – (Golde et al, 1980)], several studies have reported the
existence of a putative EPA/TIMP-1 receptor (Avalos et al, 1988;
Chesler et al, 1995; Luparello et al, 1999). However, none of these
reports have been independently verified, and no receptor has
been cloned. Some experiments have been interpreted as evidence
that the inhibitory activity and the growth-promoting activity were
independent functions of TIMP-1 (Hayakawa et al, 1994; Chesler
et al, 1995). The publication by Chesler et al (1995) dealt with the
erythroid potentiation activity measured in nucleated cells isolated
from human peripheral blood. The critical observation was that
TIMP-1 causes an increased level of differentiation in these cells,
increasing the number of erythroid precursors, independent of its
MMP inhibitory activity; an increase in the rate of cell proliferation
was not documented. In the Hayakawa et al (1994) paper, TIMP-1
was denatured and the sulphydral groups were alkylated. This
alkylated form lacked the ability to inhibit MMPs and yet could
could stimulate DNA synthesis in Raji cells, albeit much less
effectively than the unalkylated form. Neither of these reports is
contradicted by the results reported here.
The data in Figure 2A and B suggests that TIMP-1 stimulates the
metabolism and proliferation of the human breast cancer cells
studied here through its ability to inhibit an MP. Two synthetic
broad-spectrum MP inhibitors, GM6001 and Batimastat (data not
shown for Batimastat) were found to augment cellular proliferation
at about the same molar concentration as TIMP-1, albeit to a lesser
extent. This growth stimulation was demonstrated using two
separate anabolic assays based on two different principles,
mitochondrial activity and DNA synthesis. Stimulation of meta-
bolic activity preceded the increase in DNA synthesis. These data
suggest that both TIMP-1 and the synthetic MP inhibitors act on
the same target or group of targets.
To confirm that the action of the synthetic MP inhibitors
depended on their ability to inhibit MPs, an inactive derivative was
also studied (Figure 2E and F). This inactive derivative, although
similar in structure to GM6001, has been shown to be inactive
against the same MMPs that GM6001 inhibits (Jung et al, 2002). It
was unable to stimulate Alamar Blue reduction or [
3H]thymidine
incorporation. Decreased apoptosis did not appear to be
responsible for the increase in metabolic activity and DNA
synthesis induced by TIMP-1 (Figure 3).
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Figure 3 Apoptosis levels of differentially treated MDA-MB-435 cells as
measured by cytoplasmic nucleosome detection. The histogram shows the
percent of cytoplasmic nucleosomes detected in differentially treated
MDA-MB-435 cells normalised to serum-free medium plus 1%BSA. The
assay was done as described in the Materials and Methods section. Cells
treated with TIMP-1, GM6001, or GM6001* (all were added at a
concentration of 4nM) were all grown in serum-free medium with 1%BSA.
There is no statistically significant difference in the level of apoptosis as
measured by cytoplasmic nucleosome accumulation between cells grown
in serum-free medium with 1%BSA and cells grown in the same medium
with TIMP-1, GM6001, or GM6001* added. (100% represents an
OD405¼0.45).
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Figure 4 Action of signal transduction inhibitors on the ability of TIMP-1
to stimulate mitochondrial respiration. Signal transduction inhibitors were
added (LY294002, 50mM; H9, 100mM, genestein, 10mM; SB203580, 10mM
and U0126, 50mM) and incubated with the cells for 1h prior to TIMP-1
addition. The Alamar Blue assay was done as described in the Materials and
Methods section. The black bars show the metabolic activity of cells in the
presence of the indicated signal transduction inhibitor alone; the grey bars
show the activity when TIMP-1 is present. All cultures were incubated for
6h from the time of TIMP-1 addition. The leftmost pair of bars in the graph
show the activity in the absence of any signal transduction inhibitor. The
extent of Alamar Blue reduction in the presence of the different signal
transduction inhibitors did not differ by more than 10% from the control
lacking any inhibition.
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p38 kinase activity
In order to determine which signal transduction pathways were
required for the response to TIMP-1, we employed both specific
and general signal transduction inhibitors. Although several of
them partially inhibited Alamar Blue reduction (noted in the
legend to Figure 4), the effect on TIMP-1 signalling was quite
unambiguous. The specific signal transduction inhibitors for MEK
and p38 kinase both completely inhibited the TIMP-1 signal.
Additionally, the general tyrosine phosphorylation inhibitor,
Genistein, also abolished the TIMP-1 response. These data together
strongly implicate MEK and p38 kinase signal transduction
pathways in mediating the growth stimulus delivered by TIMP-1.
Other signal transduction inhibitors were also tested. These
included LY294002, a specific inhibitor of PI3-kinase and H-9,
which targets PKC and several other protein kinases. Pathways
utilising PI3-K and PKC did not contribute substantially to the
metabolic response elicited by TIMP-1.
Activity assays for the ERK1/2 and p38 kinases showed that
TIMP-1 and GM6001 activated ERK1/2 and p38 kinases with
different kinetics over the 30min time frame (Figure 5). Also,
interestingly, while the inactive derivative of GM6001 lacked the
ability to activate ERK1/2 and to elicit a metabolic response, it
nevertheless appeared able to activate p38. These differences reveal
surprising complexity in the response of the cell to these MP
inhibitors. Nevertheless, these data together with the signal
transduction data indicate that activation of both ERK1/2 and
p38 kinases is necessary for TIMP-1 stimulated proliferation to
occur in treated cells, and they are consistent with the hypothesis
that the synthetic inhibitors are acting through the same pathways
as TIMP-1.
Mechanisms of TIMP-1 action
How can inhibition of an MP result in increased growth of a cell?
Fowlkes and Winkler (2002) have recently reviewed how members
of the metzincin family (MMPs, adamalysin-related proteinases)
affect the availability of growth factors and cytokines. One
possibility is that TIMP-1 prevents the degradation of a newly
synthesised growth factor by a constitutively active MP, an ADAM
for example. There are several examples of growth factors that MPs
are capable of modifying, for example, FGF-R1, Pro-TGF-b2, and
IGF/IGFBPs (McCawley and Matrisian, 2001). Another potential
mechanism could be that TIMP-1 prevents the cleavage of a cell
surface receptor that when activated by, for example, a ligand on
another cell, stimulates proliferation. This mechanism relates to
receptor shedding, a process used by some cells to regulate signal
transduction pathways (Tokumaru et al, 2000; Chen et al, 2001).
Some MPs are capable of cleaving some cell surface receptors
(Smith et al, 1997; Lombard et al, 1998).
A final more speculative mechanism would be that TIMP-1 acts
by binding to a membrane-type MMP and causing the activation of
a signal transduction pathway through the cytoplasmic domain of
the membrane-type MMP. This is more speculative in that the two
MT-MMPs known to interact with TIMP-1 (MT4-MMP and MT6-
MMP) are not known to be capable of stimulating an intracellular
signalling pathway (Baker et al, 2002). In a real-time screen of
MMP mRNA levels in these cells, mRNAs encoding MMP13
(collagenase 3) and MMP17 (MT4-MMP) were the most abundant
(D Edwards, University of East Anglia, personal communication).
This proposed pathway could, for example, lead to the upregula-
tion of growth factor genes or the downregulation of growth
inhibitor genes. The cytoplasmic domains of membrane-type
MMPs appear to have some function in the regulation of the
membrane-type MMPs themselves (Lehti et al, 2000, 2002). Further
research is needed to elucidate the mechanism by which TIMP-1
‘signals’ by inhibiting an MP. This information may be important
for understanding why increased expression of TIMP-1 in some
cancer patients is linked to a poor prognosis (Ree et al, 1997;
McCarthy et al, 1999; Denhardt, 2000; Nakopoulou et al, 2002).
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Figure 5 ERK activity is transiently increased at 20min and p38 kinase
activity is increased at 20 and 30min post-treatment with TIMP-1 or
GM6001. Kinase activity assays were performed as described in Materials
and Methods. The Western blots shown in panel (A) indicate the level of
ERK activity associated with MDA-MB-435 cells. The bands are
phosphorylated recombinant Elk-1, which was phosphorylated by ERK
immunoprecipitated from MDA-MB-435 cells. The first two lanes of each
treatment set represent samples taken at 20min post-treatment and the
second two lanes of each treatment set represent samples taken at 30min.
Control and treated samples alternate as indicated in the figure.
Densitometry data for the ERK activity assay are shown in panel (B).
They indicate a two-fold increase in ERK activity for both TIMP-1 and
GM6001 at 20min relative to an untreated control. Panel (C) shows the
level of p38 kinase activity as measured by recombinant ATF-2
phosphorylated by immunoprecipitated p38 kinase from MDA-MB-435
cells. Panel (D) shows densitometry data for p38 kinase assays. There is a
clear two-fold increase in p38 kinase activity for all three treatments relative
to an untreated control.
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